AzurRx BioPharma appoints Terry Coelho to its Board of Directors, expanding board to seven

GridAI Technologies Corp.

Board increased from 6 to 7 directors; Coelho appointed to fill new vacancy effective August 11, 2021.
Terry Coelho is EVP and CFO of BioDelivery Sciences (NASDAQ: BDSI), with over 30 years of financial and operational experience.
Coelho will serve on the Audit Committee and Compensation Committee; annual retainer of $60,000 (pro-rated).
She previously held senior roles at Novartis, Balchem, Diversey, and Sealed Air.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Terry Coelho

Director

GRDX · GridAI Technologies Corp.

Effective: 2021-08-11
Filed: August 16, 2021, 7:59 PM ET

On August 11, 2021, the Board of Directors (the “Board”) of AzurRx BioPharma, Inc. (the “Company”) approved, effective immediately, an increase in the size of the Board from six directors to seven directors and appointed Terry Coelho, age 60, to serve as a member of the Board to fill the newly-created vacancy.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Terry Coelho was appointed as Director at GridAI Technologies Corp..

Action: appointed
Role: Director

Exact text from the filing

On August 11, 2021, the Board of Directors (the “Board”) of AzurRx BioPharma, Inc. (the “Company”) approved, effective immediately, an increase in the size of the Board from six directors to seven directors and appointed Terry Coelho, age 60, to serve as a member of the Board to fill the newly-created vacancy.

View on SEC.gov

GridAI Technologies Corp. filing history →

Source: SEC EDGAR

accession 0001654954-21-009075

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.